Skip to main content
رجوع
Watch Compare

Theriva Biologics, Inc.

جودة البيانات: 83%
TOVX
NYSE Manufacturing Chemicals
KWD 0.24
▼ KWD 0.06 (-19.19%)
القيمة السوقية: 11.01 M
السعر
KWD 0.24
القيمة السوقية
11.01 M
نطاق اليوم
KWD 0.24 — KWD 0.28
نطاق 52 أسبوعًا
KWD 0.16 — KWD 1.50
حجم التداول
4,767,400
فتح KWD 0.28
متوسط 50 يوم / 200 يوم
KWD 0.20
23.08% above
متوسط 50 يوم / 200 يوم
KWD 0.31
23.69% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -16.70 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-273.48%
أقل من متوسط القطاع (-53.41%)
ROIC-87.82%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio0.90
Interest Coverage-394.28

التقييم

PE (TTM)
-0.46
أعلى من متوسط القطاع (-1.48)
P/B Ratio1.63
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.5 -1.5
P/B 1.6 1.6
ROE % -273.5 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -23.74 M
ROE -273.48% ROA -71.22%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -16.70 M
ROIC -87.82% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.90
Interest Coverage -394.28 Asset Turnover N/A
Working Capital -1.10 M Tangible Book Value -12.88 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.46 Forward P/E N/A
P/B Ratio 1.63 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -151.66%
Market Cap 11.01 M Enterprise Value 3.49 M
Per Share
EPS (Diluted TTM) -2.08 Revenue / Share N/A
FCF / Share -0.36 OCF / Share -0.36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 70.37%
SBC-Adj. FCF -17.38 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -23.74 M -25.65 M -18.35 M -19.69 M -14.27 M
EPS (Diluted) -2.08 -19.03 -1.14 -1.31 -0.19
Gross Profit — — — — —
Operating Income -24.05 M -26.35 M -21.43 M -21.58 M -14.27 M
EBITDA — — — — —
R&D Expenses 8.60 M 12.03 M 14.31 M 11.72 M 7.80 M
SG&A Expenses — — — — —
D&A 108,000.0 137,000.0 135,000.0 85,000.0 87,000.0
Interest Expense 61,000.0 — — — —
Income Tax — 0.0 -1.64 M -1.43 M 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 38.24 M 35.35 M 55.22 M 71.86 M 70.37 M
Total Liabilities 22.86 M 16.29 M 15.52 M 17.30 M 4.96 M
Shareholders' Equity 15.38 M 19.07 M 36.96 M 56.39 M 65.41 M
Total Debt 1.67 M 92,000.0 225,000.0 278,000.0 —
Cash & Equivalents 13.06 M 11.61 M 23.18 M 41.79 M 67.33 M
Current Assets 17.47 M 16.28 M 27.40 M 45.52 M 68.86 M
Current Liabilities 10.01 M 7.59 M 6.74 M 7.06 M 3.55 M